The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Insights into the biology of pediatric MDS
Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, provides a comparison between myelodysplastic syndromes (MDS) in the pediatric and adult settings. Dr Hasserjian talks on distinctions in genetic background, with germline predispositions identified in a larger proportion of pediatric patients. Dr Hasserjian also comments on differences in the International Consensus Classification (ICC) of MDS, explaining that the MDS/acute myeloid leukemia (AML) entity does not apply to pediatric patients due to the comparatively slower progression of MDS to AML in this population. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
